Themis Symposium on Novel Immuno-stimulatory Cancer Therapies

To register for the event, please send an email to

3.00 pm – 3.10 pm
Welcome and Introduction (Erich Tauber, CEO, Themis Bioscience)
3.10 pm – 3.35 pm
Current Hurdles in Cancer Therapy and latest developments in immuno-oncology (Carl D. Novina, Dana Faber Cancer Institute)
3.35 pm – 4.00 pm
Challenges in GI tumor (immune-)therapy and prospects of improved/novel immunotherapies (Richard D. Kim, Moffitt Cancer Center)
4.00 pm – 4:15 pm
4.15 pm – 4.40 pm
The measles vector and its unique properties to create novel infectious disease and cancer therapies (Paul Duprex, University of Pittsburgh)
4.40pm – 4.55 pm
Themis’ IO Pipeline (Jochen Stritzker, SVP Immunotherapy, Themis Bioscience)
4.55 pm – 5.30 pm
Q&A and Discussion

Moderated by Christian Mandl (SAB chair, Themis Bioscience)